Cantor Fitzgerald Estimates Belite Bio FY2025 Earnings

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Belite Bio in a research note issued on Monday, November 24th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will post earnings of ($2.26) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $154.00 price target on the stock. The consensus estimate for Belite Bio’s current full-year earnings is ($1.17) per share. Cantor Fitzgerald also issued estimates for Belite Bio’s FY2026 earnings at ($3.04) EPS.

Other equities analysts have also recently issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Belite Bio in a research report on Wednesday, October 8th. Zacks Research raised Belite Bio from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. Wall Street Zen downgraded shares of Belite Bio from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. HC Wainwright dropped their target price on shares of Belite Bio from $100.00 to $98.00 and set a “buy” rating for the company in a research report on Monday, September 15th. Finally, Mizuho assumed coverage on shares of Belite Bio in a report on Thursday, November 20th. They issued a “neutral” rating and a $105.00 price target on the stock. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $122.25.

Belite Bio Stock Performance

Belite Bio stock opened at $129.62 on Wednesday. Belite Bio has a fifty-two week low of $49.00 and a fifty-two week high of $144.99. The stock has a market cap of $4.52 billion, a P/E ratio of -67.51 and a beta of -1.42. The firm’s fifty day moving average price is $94.54 and its 200-day moving average price is $74.45.

Belite Bio (NASDAQ:BLTE) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.12).

Hedge Funds Weigh In On Belite Bio

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP purchased a new position in Belite Bio in the 3rd quarter worth $23,125,000. Polymer Capital Management HK LTD bought a new position in Belite Bio during the 3rd quarter worth approximately $538,000. RA Capital Management L.P. bought a new position in Belite Bio during the 3rd quarter worth approximately $64,750,000. Millennium Management LLC purchased a new position in Belite Bio in the 3rd quarter worth approximately $1,535,000. Finally, Citadel Advisors LLC lifted its position in Belite Bio by 45.2% in the third quarter. Citadel Advisors LLC now owns 10,827 shares of the company’s stock valued at $801,000 after purchasing an additional 3,371 shares during the last quarter. Institutional investors own 0.53% of the company’s stock.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.